Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cardio II Midterm > Drugs Used in Chronic Ischemic Heart Disease -DSA > Flashcards

Drugs Used in Chronic Ischemic Heart Disease -DSA Flashcards

1
Q

Approach to treating angina pectoris

A

1 - increase coronary blood flow

2 - reduce myocardial oxygen demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Determinants of myocardial oxygen demand

A

Heart rage
contractility
preload
afterload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Drug classes used in chronic IHD

A

Nitrates - nitrovasodilators
CCB
Beta blockers
Ranolazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Nitrovasodilators

A

Nitroglycerin
Isosorbide dinitrate
Isosorbide mononitrate - active metabolite of dinitrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Nitrovasodilator pharmacokinetics

A

Significant first-pass metabolism - high nitrate reductase activity in the liver (Nitrate reeducates activity in saturable)
Bioavailability with oral route is low - other routes avoid first pass metabolism
partially denigrated metabolites have activity and longer half-lives
Isosorbide mononitrate is poor substrate of nitrate reductase - high bioavailability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Nitrovasodilator pharmacodynamics - MOA

A

– Unknown enzymatic reaction releases NO (or other active metabolite – nitrosothiol?)
• The role of mitochondrial aldehyde dehydrogenase 2 (ADH2)

– Thiol compounds are needed to release NO from nitrates

– Vascular smooth muscle relaxation by NO

– Sensitivity of vasculature to nitrate-induced vasodilation:
Veins > Large arteries > Small arteries and arterioles

– No “coronary steal” phenomenon

– Inhibit platelet aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Beneficial action of nitrovasodilators in angina

A

decreased myocardial oxygen demand

Relaxation of vascular smooth muscle - dilation of veins (major effect) and dilation of arteries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dilation of veins with nitrovasodilators for treatment of angina

A

major effect

increased venous capacitance

reduced ventricular preload

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dilations of arteries with nitrovasodilators for treatment of angina

A

higher concentrations of nitrates are needed compared to venous dilation

reduced arterial pressure and after load

may dilate large epicardial coronary arteries

No significant increase in coronary blood flow into the ischemic area in atherosclerotic angina

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Nitrate effects in angina of effort

A

decreased preload

decreased oxygen demand

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Nitrate effects on vasospastic angina

A

relaxation of coronary artery vascular smooth muscle

Relieving coronary artery spasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Clinical use of nitrovasodilators

A

short-acting formulations used to relieve angina attack

Long-acting preparations may be used to prevent attacks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Development of nitrate tolerance

A
  • Depletion of thiol compounds
  • Increased generation of oxygen radicals

• Reflex activation of sympathetic nervous system (tachycardia, decreased
coronary blood supply)

• Retention of salt and water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Adverse effects of nitrates

A
  • Headache (meningeal vasodilation)
  • Orthostatic hypotension

• Increased sympathetic discharge
– Tachycardia
– Increased cardiac contractility

• Increased renal Na+ and H2O reabsorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Nitrate drug interactions

A

ED treatment:

– Sildenafil, vardenafil, tadalafil
• Inhibit cGMP-phosphodiesterase-5, increases cGMP
• Minimal effects on hemodynamics when administered alone in men
with coronary artery disease
– Combination with nitrates causes severe increase in cGMP and a dramatic drop in BP

– Acute myocardial infarction cases have been reported

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Non-cardioactive calcium channel blockers (dihydropyridines)

A

Amlodipine - long acting (t1/2 30-50 h)
Nifedipine - short acting (t1/2 4 h)
Nicardipine - short acting (t1/2 2-4 h)

17
Q

Cardioactive calcium channel blockers (non-dihydropyridines)

A

Diltiazem

Verapamil

18
Q

Calcium channel blockers MOA

A

• Ca2+ mediates smooth muscle contraction; enters cells via voltage-dependent
calcium channels

• CCBs block Ca2+ entry to relax vascular smooth muscle

19
Q

Anti-Anginal mechanisms of CCBs - decreased myocardial oxygen demand

A

– Dilation of peripheral arterioles
• Decreased PVR and afterload, decreased blood pressure
• Arterioles more affected than veins (less orthostatic hypotension)
• Dihydropyridines are more potent vasodilators

– Decreased cardiac contractility and heart rate (observed with cardioactive CCBs)

20
Q

Anti-antinal mechanisms of CCB - increased blood supply

A

Dilation of coronary arteries relieves local spasms (this mechanism may operate in vasospastic (Prinzmetal) angina and NOT in atherosclerotic angina)

21
Q

Major adverse effects of CCB

A

Cardiac depression, cardiac arrest, acute heart failure (cardioactive CCBs)

Bradyarrhythmias, AV block (cardioactive CCBs)

Short acting dihydropyridine CCBs - vasodilation triggers reflex sympathetic activation

Nifedipine - immediate release: increases risk of MI in patient with HTN, slow release and long acting dihydropyridines better tolerated

22
Q

Minor adverse effects of CCB

A

Flushing, HA, anorexia, dizziness
Peripheral edema
Constipation

23
Q

Beta blockers indicated in angina

A

Propranolol
Nadolol
Metoprolol
Atenolol

24
Q

Beta blocker MOA in angina

A

decreased myocardial oxygen demand

– Decrease in HR leads to improved myocardial perfusion and reduced
oxygen demand at rest and during exercise

– Decrease in contractility

– Decrease in blood pressure leads to reduced afterload

25
Q

Adverse effects of beta-blockers

A

– Reduced cardiac output
– Bronchoconstriction
– Impaired liver glucose mobilization
– Produce an unfavorable blood lipoprotein profile (increase VLDL and
decrease HDL)
– Sedation, depression
– Withdrawal syndrome associated with sympathetic hyperresponsiveness

26
Q

Contraindications of beta-blockers

A 
– Asthma
– Peripheral vascular disease
– Raynaud’s syndrome
– Type 1 diabetics on insulin
– Bradyarrhythmias and AV conduction abnormalities
– Severe depression of cardiac function
27
Q

Effects of nitrates alone on heart rate, arterial pressure, end-diastolic volume, contractility, and ejection time in angina pectoris

A

Heart Rate: Reflex increase (not desirable)
Arterial pressure: Decrease
End-diastolic Volume: Decrease
Contractility: Reflex increase (not desirable)
Ejection time: Decrease

28
Q

Effects of Beta Blockers or CCBs on heart rate, arterial pressure, end-diastolic volume, contractility, and ejection time in angina pectoris

A 
Heart Rate: Decrease
Arterial pressure: Decrease
End-diastolic Volume: Increase (not desirable)
Contractility: Decrease
Ejection time: Increase (not desirable)
29
Q

Effects of nitrates with beta blockers or CCBs on heart rate, arterial pressure, end-diastolic volume, contractility, and ejection time in angina pectoris

A 
Heart Rate: Decrease
Arterial pressure: Decrease
End-diastolic Volume: none or decrease
Contractility: None
Ejection time: None
30
Q

Ranolazine MOA

A

– Inhibits late Na+ current in cardiomyocytes
– Ischemic myocardium is often partially depolarized
– Na+ channel in cardiomyocytes is voltage-gated
– Late Na+ current is enhanced in ischemic myocardium and brings about Ca2+ overload and repolarization abnormalities
– Ranolazine normalizes repolarization of cardiac myocytes and reduces
mechanical dysfunction

31
Q

Ranolazine does not affect…

A
  • Heart rate
  • General inotropic state of myocardium
  • Coronary blood flow
  • Peripheral hemodynamics
32
Q

Clinical use of Ranolazine

A

– Stable angina which is refractory to standard medications

– Decreases angina episodes and improves exercise tolerance in patients taking nitrates, or amlodipine, or atenolol

33
Q

Adverse Effects of Ranolazine

A 
– QT interval prolongation – may trigger polymorphic ventricular arrhythmias
– Constipation
– Nausea
– Dizziness
– Headache
34
Q

Drug interactions of Ranolazine

A

– Metabolized by CYP3A4/5 – interaction with drugs that modulate the activity of these enzymes
• Do not combine with strong CYP3A inhibitors: antifungal azoles,
verapamil

– Ranolazine inhibits CYP2D6
• Increases half-life of Amitriptyline, Fluoxetine, Metoprolol, opioid drugs

– Drugs that prolong QT interval – certain antiarrhythmic (Quinidine) and antipsychotic drugs (Thioridazine) – may trigger ventricular arrhythmias

Cardio II Midterm (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions